Skip to main content

The first effective remedy for acute pancreatitis disease


ChemICare is a high-tech spin-off of the University of Piemonte Orientale and has patented and preclinically developed small molecules that are unique in their capacity to modulate calcium ions uptake in cellular processes. Calcium overload associated with Store-Operated Calcium Entry hyper-activation has been proved to be to be the key trigger in a cluster of diseases, including Acute Pancreatitis, which affects over 10 million people globally and is the most common gastroenterology discharge diagnosis in Europe and the US. AP is associated with significant disease burden, emergency room visits, frequent hospitalizations, and patients often undergo endoscopic and surgical procedures and are admitted to intensive care, costing more than 20 B€ yearly to National Healthcare Services. Preclinical data obtained so far demonstrate that drug candidate 39 represents a breakthrough innovation in the field of pharmacological therapies for AP. We are now in the process of generating the last data to complete the preclinical regulatory dossier, which will pave the way for the Phase I and II clinical trials which will lead to an out-license agreement to a large pharma company prior to the initiation of Phase III. The revenues will therefore be reinvested to finance development of the same technology for other therapeutic indications associated with calcium overload (e.g. Duchenne Muscular Dystrophy and Tubular Aggregate Myopathy). This Phase 1 is of utmost importance to validate the market position of ChemICare molecules, apply for orphan designation, and plan the preclinical study necessary to prepare the clinical validation Phases in the frame of the Phase 2. Our goal is to have a solution ready for the market by 2024, which will be cost-effective for health providers and deliver optimal care to patients with AP. Such rapid time-to-market is possible because both EMA and FDA have accelerated paths for rare disease solutions that we will take advantage of.

Field of science

  • /medical and health sciences/basic medicine/neurology/muscular dystrophy
  • /medical and health sciences/basic medicine/pathology
  • /medical and health sciences/basic medicine/immunology/autoimmune diseases
  • /medical and health sciences/clinical medicine/gastroenterology
  • /medical and health sciences/health sciences/health care services
  • /medical and health sciences/clinical medicine/surgery/surgical procedure
  • /social sciences/sociology/demography/mortality
  • /medical and health sciences/clinical medicine/critical care medicine
  • /medical and health sciences/health sciences/inflammatory diseases
  • /natural sciences/chemical sciences/inorganic chemistry/inorganic compounds

Call for proposal

See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1


Via Amico Canobio 4/6
28100 Novara
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000